Impaired postprandial releases/syntheses of ghrelin and PYY3-36 and blunted responses to exogenous ghrelin and PYY3-36 in a rodent model of diet-induced obesity

Journal of Gastroenterology and Hepatology (Australia)

Volumn 26, Issue 4, 2011, Pages 700-705

  Xu, Junying ^a,b   Mcnearney, Terry A ^b   Chen, Jdz ^b  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Diet induced obesity; Food response; Ghrelin; PYY

Indexed keywords

GHRELIN; GLUCOSE; PEPTIDE YY [3-36];

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; COLON; DIET RESTRICTION; FOOD INTAKE; GLUCOSE BLOOD LEVEL; MALE; NONHUMAN; OBESITY; PRIORITY JOURNAL; RAT; STOMACH FUNDUS;

EID: 79952844914     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2010.06563.x     Document Type: Article

References (32)

1. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 2006; 13: 1549-55.
2. Schwartz GJ. Biology of eating behavior in obesity. Obesity 2004; 12: 102S-6S.
3. Schwartz MW, Woods SC, Porte D, Seeley RJ, Baskin DJ. Central nervous system control of food intake. Nature 2000; 404: 661-71.
4. Orr J, Davy B. Diet dietary influences on peripheral hormones regulating energy intake: potential applications for weight management. J. Am. Diet. Assoc. 2005; 105: 1115-24.
5. Kojima M, Kangawa K. Ghrelin, an orexigenic signaling molecule from the gastrointestinal tract. Curr. Opin. Pharmacol. 2002; 2: 665-8.
6. Kojima M, Hosoda H, Fate Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999; 402: 656-60.
7. Cummings DE, Purnell JQ, Frayo RS, Schmidova K, Wisse BE, Weigle DS. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 2001; 50: 1714-19.
8. English PJ, Ghatel MA, Malik IA, Bloom SR, Wilding JPH. Food fails to suppress ghrelin levels in obese humans. J. Clin. Endocrinol. Metab. 2002; 87: 2984-7.
9. Levin BE, Dunn-Meynell AA, Ricci MR, Cummings DE. Abnormalities of leptin and ghrelin regulation in obesity-prone juvenile rats. Am. J. Physiol. Endocrinol. Metab. 2003; 285: E949-57.
10. Stock S, Leichner P, Wong AC etal. Peptide YY, glucose-dependent insulinotropic polypeptide, and hunger responses to a mixed meal in anorexic, obese, and control female adolescents. J. Clin. Endocrinol. Metab. 2005; 90: 2161-8.
11. Batterham RL, Cowley MA, Small CJ etal. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 2002; 418: 650-4.
12. Batterham RL, Cohen MA, Ellis SM etal. Inhibition of food intake in obese subjects by peptide YY3-36. N. Engl. J. Med. 2003; 349: 941-8.
13. Cox JE, Randich A. Enhancement of feeding suppression by PYY(3-36) in rats with area postrema ablations. Peptides 2004; 25: 985-9.
14. Riediger T, Bothe C, Becskei C, Lutz TA. Peptide YY directly inhibits ghrelin-activated neurons of the arcuate nucleus and reverses fasting-induced c-Fos expression. Neuroendocrinology 2004; 79: 317-26.
15. Pittner RA, Moore CX, Bhavsar SP etal. Effects of PYY [3-36] in rodent models of diabetes and obesity. Int. J. Obes. Relat. Metab. Disord. 2004; 28: 963-71.
16. Chelikani PK, Haver AC, Reidelberger RD. Intravenous infusion of peptide YY (3-36) potently inhibits food intake in rats. Endocrinology 2005; 146: 879-88.
17. Le Roux CW, Batterham RL, Aylwin SJ etal. Attenuated peptide YY release in obese subjects is associated with reduced satiety. Endocrinology 2006; 147: 3-8.
18. Schwartz MW, Morton GJ. Obesity: keeping hunger at bay. Nature 2002; 418: 595-7.
19. Korner J, Bessler M, Cirilo LJ etal. Effects of Roux-en-Y gastric bypass surgery on fasting and postprandial concentrations of plasma ghrelin, peptide YY, and insulin. J. Clin. Endocrinol. Metab. 2005; 90: 359-65.
20. Vrang N, Madsen AN, Tang-Christensen M, Hansen G, Larsen PJ. PYY (3-36) reduces food intake and body weight and improves insulin sensitivity in rodent models of diet-induced obesity. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2006; 291: R367-75.
21. Teske JA, Levine AS, Kuskowski M, Levine JA, Kotz CM. Elevated hypothalamic orexin signaling, sensitivity to orexin A, and spontaneous physical activity in obesity-resistant rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2006; 291: R889-99.
22. Neary NM, Druce MR, Small CJ, Bloom SR. Acylated ghrelin stimulates food intake in the fed and fasted states but desacylated ghrelin has no effect. Gut 2006; 55: 135.
23. Nordheim U, Hofbauer KG. Stimulation of NPY Y2 receptors by PYY3-36 reveals divergent cardiovascular effects of endogenous NPY in rats on different dietary regimens. Am. J. Physiol. 2004; 286: R138-42.
24. Date Y, Toshinai K, Koda S etal. Peripheral interaction of ghrelin with cholecystokinin on feeding regulation. Endocrinology 2005; 146: 3518-25.
25. Hofbauer KH, Jensen BL, Kurtz A etal. Tissue hypoxygenation activates the adrenomedullin system in vivo. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2000; 278: R513-19.
26. Lee HM, Wang G, Englander EW etal. Ghrelin, a new gastrointestinal endocrine peptide that stimulates insulin secretion: enteric distribution, ontogeny, influence of endocrine and dietary manipulations. Endocrinology 2002; 143: 185-90.
27. Nakazato M, Murakami N, Date Y etal. A role for ghrelin in the central regulation of feeding. Nature 2001; 409: 194-8.
28. Zhu W, Yuexin Y, Xuesong X etal. Estimation of the normal range of blood glucose in rats. J. Hyg. Res. 2010; 39: 4-6.
29. Tschöp M, Wawarta R, Riepl RL etal. Postprandial decrease of circulating human ghrelin levels. J. Endocrinol. Invest. 2001; 24: RC19-21.
30. Cong WN, Golden E, Pantaleo N etal. Ghrelin receptor signaling: a promising therapeutic target for metabolic syndrome and cognitive dysfunction. CNS Neurol. Disord. drug targets 2010; 9: 557-63.
31. Tschop M, Castaneda TR, Joost HG etal. Physiology: does gut hormone PYY3-36 decrease food intake in rodents. Nature 2004; 430: 165-7.
32. Field BC, Wren AM, Peters V etal. PYY3-36 and oxyntomodulin can be additive in their effect on food intake in overweight and obese humans. Diabetes 2010; 59: 1635-9.